The major driving force behind the revolution inpatient care is technology. Nowadays, ground-breaking healthcare apps on mobile phones and wearable devices are giving some autonomy to the patients, by increasing their involvement in healthcare, as well as, in enhancing their general health and wellness. In the meantime, there is also tapping of robots into the hospitals across the world, facilitating shortages of personnel, as well as, allowing better care for patients.
However, this has marked just the beginning of evolution. The path for the entry of smarter robots into the healthcare sector is paved by artificial intelligence. Other than this, enhanced drug development, state-of-the-art wearable, and the basic change in the way the patient care is approached by us are also facilitated by artificial intelligence.
Exscientia is at the forefront of Artificial Intelligence-driven drug discovery and design. As at 8th January 2019, Frontier IP Group Plc (LON:FIPP) have a 3.3% holding in Exscientia. Frontier IP Group, through its subsidiaries, engages in assisting universities, research institutions, and companies in the commercialization and exploitation of their intellectual property (IP) in the United Kingdom.